Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
In addressing the fourth-quarter figures for Eylea three weeks earlier at the J.P. Morgan Healthcare Conference ... such as the performance of its cancer drug Libtayo. In the fourth quarter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback